text:
Hotel & Restaurant Kronprinz, Falkensee
- Free WiFi
Main amenities
- 26 smoke-free guestrooms
- Restaurant and bar/lounge
- Breakfast available
- Daily housekeeping
- Laundry service
- Conference space
- Free newspapers in the lobby
- Limited hour front desk
For families
- Free cribs/infant beds
- Connecting/adjoining rooms available
- Private bathroom
- Television
- Free toiletries
- Daily housekeeping
What's around
- Spandau Citadel (7.1 mi / 11.5 km)
- Olympic Stadium (10.2 mi / 16.5 km)
- Schloss Charlottenburg (11.7 mi / 18.8 km)
- Berlin Zoo (13.4 mi / 21.6 km)
- Waldbuhne (9.9 mi / 15.9 km)
- Berlin (TXL-Tegel) 30-min drive; 11.5 miles/18.5 km
- Berlin (SXF-Schoenefeld) 47-min drive; 28 miles/45.1 km
- Berlin Spandau Station 18-min drive; 7 miles/11.2 km
- Berlin Charlottenburg Station 32-min drive; 13.7 miles/22.1 km
- Berlin-Zoologischer Garten Station 36-min drive; 14.9 miles/24 km
Hotel & Restaurant Kronprinz, Falkensee
Hotel Info: 866-539-8117from $77
- Single Room
- Double Room
Also popular with travelers from the USA
At a glance
Key facts
Hotel size
- This hotel has 26 rooms
- This hotel is arranged over 4 floors
- Check-in time 2 PM-midnight
- Check-out time is 11 AM
- Express check-in/out
Required at check in
- Credit card or cash deposit required
- Government-issued photo ID required
Travelling with others
- One child (18 years old and younger) stays free when occupying the parent or guardian's room, using existing bedding
- Pets allowed (dogs and cats only) *
- Restrictions apply *
- 2 per room
- Free WiFi in public areas
- Free WiFi in rooms
Other information
- Smoke-free property
In the hotel
- Buffet breakfast daily (surcharge)
- Restaurant
- Bar/lounge
- Conference space
- Conference space size (feet) -
- Front desk (limited hours)
- Dry cleaning/laundry service
- Free newspapers in lobby
- Number of buildings/towers - 1
In the room
- Minibar
- Iron/ironing board (on request)
- Hypo-allergenic bedding available
- Balcony or patio
- Private bathroom
- Bathtub or shower
- Free toiletries
- Hair dryer
- Desk
- Free newspaper
- Free WiFi
- Phone
- Free bottled water
- Daily housekeeping
- Connecting/adjoining rooms available
Special features
DiningFalkensee - This restaurant specializes in international cuisine and serves breakfast, lunch, dinner, and light fare. Guests can order drinks at the bar and enjoy alfresco dining (weather permitting). A children's menu is available.
Hotel & Restaurant Kronprinz, Falkensee's small print
Also known as
- Hotel Kronprinz Falkensee
- Kronprinz Falkensee
The property has connecting/adjoining rooms, which are subject to availability and can be requested by contacting the property using the number on the booking confirmation.
Pet-friendly rooms can be requested by contacting the property at the number on the booking confirmation.
This property does not have elevators.
Optional extras
Rollaway beds are available for an additional charge
Buffet breakfast is offered for an extra charge of EUR 10.90 per person (approximately)
Pets are allowed for an extra charge of EUR 10 per pet, per night
We have included all charges provided to us by this hotel. However, charges can vary, for example, based on length of stay or the room you book.
More great choices
Is the description of this hotel not correct? Tell us


text:
Executive Personnel, employment agency, listed under "Employment Agencies" category, is located at 4155 E Jewell Ave Denver CO, 80222 and can be reached by 3037584602 phone number. Executive Personnel has currently 0 reviews.This business profile is not yet claimed, and if you are the owner, claim your business profile for free. If you are not the owner you can invite this business to join by email or by phone.Browse all Employment Agencies in Denver CO. Discover census data for Denver, CO.
Back to Top

subset: commoncrawl


text:
My Story Hotel Ouro, Lisbon
- Free WiFi
Main amenities
- 51 smoke-free guestrooms
- Restaurant and bar/lounge
- Breakfast available
- 24-hour front desk
- Air conditioning
- Front desk safe
- Laundry service
- Multilingual staff
- Gift shops/newsstands
- Luggage storage
- Tour/ticket assistance
- TV in a common area
For families
- Cribs/infant beds available
- Rollaway/extra beds available
- Private bathroom
- Free toiletries
- Hair dryer
- Elevator/lift
What's around
- In Baixa
- Santa Justa Elevator (0.2 mi / 0.3 km)
- Rossio Square (0.3 mi / 0.4 km)
- Lisbon Cathedral (0.3 mi / 0.5 km)
- Castle of Sao Jorge (0.8 mi / 1.3 km)
- Gulbenkian Museum (2.3 mi / 3.7 km)
- Lisbon (LIS-Humberto Delgado) 21-min drive; 4.7 miles/7.5 km
- Lisbon Rossio Station 7-min walk; 0.4 miles/0.6 km
- Lisbon Cais do Sodre Station 11-min walk; 0.5 miles/0.9 km
- Lisbon Santa Apolonia Station 21-min walk; 1.1 miles/1.7 km
- Baixa-Chiado Station 2-min walk; 0.1 miles/0.1 km
- Rossio Metro Station 6-min walk; 0.3 miles/0.5 km
- Terreiro do Paco Station 9-min walk; 0.5 miles/0.7 km
- Onsite parking not available
My Story Hotel Ouro, Lisbon
Hotel Info: 020 3027 9803from £96
- Standard Twin Room
- Double Room Single Use
- Family Room, 2 Bedrooms, Connecting Rooms (2 Bathrooms)
- Standard Double Room
Also popular with travellers from the UK
At a glance
Key facts
Hotel size
- This hotel has 51 rooms
- This hotel is arranged over 4 floors
- Check-in time 3 PM-midnight
- Check-out time is noon
Required at check in
- Credit card or cash deposit required
- Government-issued photo ID required
- Minimum check-in age is 18
Travelling with others
- Pets not allowed
Extra people
- Rollaway beds available, charges may apply*
- Free WiFi in public areas
- Free WiFi in rooms
- No parking
Other information
- Smoke-free property
In the hotel
- Buffet breakfast daily (surcharge)
- Restaurant
- Bar/lounge
- 24-hour front desk
- Tours/ticket assistance
- Dry cleaning/laundry service
- Luggage storage
- Multilingual staff
- Number of buildings/towers - 1
- Elevator/lift
- Safe-deposit box at front desk
- Television in common areas
- Accessible bathroom
- In-room accessibility
In the room
- Air conditioning
- Minibar
- Private bathroom
- Shower only
- Free toiletries
- Hair dryer
- Flat-screen TV
- Cable TV channels
- Desk
- Free WiFi
- Phone
- In-room safe
Special features
DiningMy Story Hotel Ouro - This restaurant specializes in Portuguese cuisine and serves lunch and dinner.
My Story Hotel Ouro, Lisbon's small print
Also known as
- My Story Hotel Ouro Lisbon
- My Story Hotel Ouro
- My Story Ouro Lisbon
- My Story Ouro
- My Story Ouro Lisbon
Mandatory fees
You'll be asked to pay the following charges at check in or check out:
- A tax is imposed by the city: EUR 1 per person, per night, up to 7 nights. This tax does not apply to children under 13 years of age.
Optional extras
Rollaway beds are available for EUR 12.50 per night
Buffet breakfast is offered for an extra charge of EUR 10 per person (approximately)
We have included all charges provided to us by this hotel. However, charges can vary, for example, based on length of stay or the room you book.
Recent reviews
Excellent 4.4 /5 from 193 reviews
Great location, extremely helpful staff and excellent food would definitely stay here again.
The Hotel staff were friendly, helpful and efficient. The only criticism I could make was that the room was very small made even smaller with two large suitcases!
From first arrival at reception to departure staff very helpful with details of things to do, transport and places to eat. run by a different company the restaurant staff where also very good. Especially the young lady who made the cocktails. The breakfast had excellent selection from hot eggs, bacon, mushrooms and all the usual continental stuff. Rooms are small but very clean and all you need for a good nights sleep. Hotel close to all the city centre tourist areas & 2 minutes from metro and buses.
Good modern hotel in Baixa District, a few minutes walk from the Metro, and a central area for trams and buses. Very clean and comfortable rooms, but few facilities in the room for storage and hanging of clothes. Therefore best for short city breaks. Excellent front desk staff, very helpful and accomodating. Good breakfasts, but a little cramped if the weather is not warm enough to be seated outside, although the staff are very good at keeping things going along smoothly. Highly recommended for value for money,cleanliness, situation, and excellent staff.
Whilst the room was pretty cramped, it was clean and we didn't spend much time in there anyway. It's central, helpful staff and good breakfasts - which always makes a difference! It's less than a 5 minute walk to good restaurants, the waterfront etc and a 10 minute walk from the old town with all its attractions.
Is the description of this hotel not correct? Tell us


text:
Tag Archives: Tour
Breaking News: Maddie Z Will Join Sia on Tour!
Hate to break it to you dancers, but summer's winding down. It's not all bad though—fall signals the start of … More »
#BTS: What It's Like to Tour the World with Pop Stars
Commercial dancer Melanie Mah is no stranger to dancing behind some of the music industry's most famous artists. She's worked … More »
This Selena Gomez Dancer Has a New YouTube Channel
We featured commercial diva Liana Blackburn in 2015 and she wowed us with her super-healthy, vegetable-centric diet—which she maintained while … More »
A Peek Inside NYCB Travel Cases
Is there anything more exciting than peeking into the private world of your dance idols? Nope, I don't think there … More »
The Dirt: Melanie Mah
Melanie Mah's career is basically the commercial-dance dream. After training as a ballet dancer near her hometown of Richmond … More »
On Tour with Shaping Sound
Shaping Sound Dance Company first debuted its full-length production That's Where I'll Be Waiting in 2013. Two years later, the … More »


text:
Holiday Shipping Deadlines CLOSE X
Luxe lambskin meets warm down fill in this lightweight jacket, which is finished with a detachable cashmere-and-silk hood for chic versatility.
It is our priority to provide you with the exceptional service you have come to expect from Ralph Lauren. Your feedback is important to us.
For press inquiries, e-mail us at firstname.lastname@example.com
Phone: +44 (0) 203 450 7750
Please note that RalphLauren.co.uk does not use your email for promotional purposes or disclose it to a third party. Privacy Notice.


text:
Build a royal castle fit for a king with Moon Sand! This colourful, squishy and cleverly design sand never dries out and provides hours of creative fun.
Use the tower and turret moulds to make your regal palace, then add the finishing touches with a king, queen and lots of treasure.
Moon Sand holds just like dough and does not stick or stain.
Set includes 3x colours of Moon Sand, 10x moulds and tools, and a sandbox for easy storage.


text:
Through detailed intricate histories of illicit Internet piracy networks, Digital Culture Industry goes beyond the Napster creation myth and illuminates the unseen individuals, conflict and code behind the turn to digital media distribution. By utilising the internet as an archive of digital documents, the author presents unique histories of sites such as MP3.com and The Pirate Bay, and illuminates the software, values and people behind networks such as GNUtella and BitTorrent. By examining topics such as hacker ideology, data rights management and the ownership of digital media, this book demonstrates how our relationship to media objects has been transformed by digital distribution. The book also examines the method behind the work and demonstrates how digital documents can be utilised for historical research. It argues for histories that account for detail, the unintended and the impact that code can have on the trajectory of social change.Deutsch, C. (2002) Suit Settled Over Pricing of Recordings at Big Chains. The New York Times, ... Are They Any Free-er? BoingBoing.net, available at: http:// boingboing.net/2010/01/21/drm-freekindle-book.html, last accessed 7 January 2011.
|Digital Culture Industry
|James Allen-Robertson
|Palgrave Macmillan - 2013-03-25


text:
Barton Associates
Locum Tenens
A facility in Maine is looking for a cardiologist who is able to provide one month of locum tenens coverage. This position will have the locum reading EKGs for annual wellness visits. This is a part-time position where the locum can expect to perform 20 - 28 reads per day. Candidates should be comfortable reading Echo and EKG to be qualified for this position.ResponsibilitiesAttention to Detail Job requires being careful about detail and thorough in completing work tasks.Integrity Job requires consistency of actions, methods, principles, expectations, and outcomes.Dependability Job requires having excellent attendance, being reliable, responsible, and fulfilling obligations.Analytical Thinking Job requires analyzing information and using logic to address work-related issues and problems.About Barton AssociatesFounded in 2001, Barton Associates is a leading national locum tenens physician, physician assistant, and nurse practitioner staffing and recruiting firm. Barton Associates has the experience, resources, and scale needed to efficiently match talented locum tenens physicians, dentists, physician assistants, and nurse practitioners with great healthcare facilities and practices across the United States in a wide variety of practice areas.
this is NOT an opportunity for Search Firm recruiters.
Thank you.


text:
Katie Couric's daytime debut is getting closer, and her team released another promo for her upcoming show on Monday.
In it, Couric asks, "What are the rules for dating after 40?" and, "Are there foods that can keep us looking younger?" These are some of the questions that she plans to address on "Katie," which premieres on September 10.
Couric has long said that the show will run the gamut from the silly to the serious, including issues that both she and her viewers are facing.
"I lost my husband and my sister and I've learned a lot about cancer in the course of my life," she said in January, touting the life experiences that that made her relatable to her audience. "I'm a mother of two daughters. A single parent... I have dealt with aging parents and I'm aging myself. I think I'm interested in a lot of topics a lot of people out there are dealing with, and I'm dealing with them too."
Related on HuffPost:
From Our PartnersPresented by LendingTree
Get top stories and blog posts emailed to me each day. Newsletters may offer personalized content or advertisements.Learn more


text:
|Publication number
|Publication type
|Application number
|Publication date
|Aug 8, 1989
|Filing date
|Oct 6, 1987
|Priority date
|Oct 6, 1987
|Fee status
|Publication number
|John D. Mull
|Original Assignee
|Mull John D
|Export Citation
|BiBTeX, EndNote, RefMan
|Patent Citations (6), Referenced by (45), Classifications (9), Legal Events (6)
|External Links: USPTO, USPTO Assignment, Espacenet
This invention relates generally to a device for separating plasma from red cells (erythrocytes) in blood samples.
Various blood analysis techniques require clear plasma samples free of red cells. Separation of plasma from red cells can be accomplished by various methods based on the fact that the red cells are of a higher specific gravity than the plasma. For example, if a blood sample can be allowed to stand for two or more days, the red blood cells will settle to the bottom by gravity. A faster technique is centrifugation using an ordinary laboratory centrifuge. In routine laboratory analysis, a centrifugation step does not delay the work flow. However, centrifugation does take some time (20 minutes or so) and may be unacceptable in an emergency situation, for example in an operating room. Even in non-emergency situations such as in a doctor's office, it may be desirable for the doctor himself or an assistant to be able to quickly obtain a clear plasma sample without having to send the blood sample to a laboratory.
Centrifuge devices comprising a rotor that rotates at high speed about a vertical axis have been proposed for clearing blood samples of chylomicrons (fat particles 80-500 nm diameter) prior to clinical analysis. Devices of this type are available from Beckman Instruments, Inc. of California and are described in (Ishimaru et al.) U.S. Pat. No. 4,142,670 issued Mar. 6, 1979 and (Nielsen) U.S. Pat. No. 4,177,921 issued Dec. 11, 1979. Both of these patents have been assigned to Beckman Instruments, Inc.
The Beckman chylomicron rotor receives a disposable liner in which chylomicrons are isolated by flotation. The liner has a cylindrical centre chamber and a doughnut-shaped outer chamber. The liner is made of a thin and flexible polyethylene material and flexes substantially under centrifugal force during centrifugation while being constrained by the rotor. At this time, the chylomicrons float to the centre of the liner where they are isolated. The serum can then be removed from the liner by pipette.
The invention provides a plasma separator comprising a container which is symmetrical about a normally vertical axis and which is adapted for coupling to a device capable of rotating the container at high speed about the said axis. The container is self-supporting during such rotation and defines internally a central chamber for receiving a blood sample, an annular outer chamber for receiving red blood cells separated out of the sample by rotation about said axis, and an annular passageway connecting the chambers. The central chamber has a lower wall of inverted conical shape extending to a circular edge at an upper end of the wall and at an inner and of the said passageway. The passageway extends downwardly and outwardly from the said edge to the outer chamber, the outer chamber being located at an outer end of the passageway and below the said circular edge. The container has a single opening located in a top wall above the central chamber of a size sufficient only to permit insertion of a blood sample into and removal of plasma from the central chamber.
In use, a blood sample is introduced into the central chamber through the opening in the top wall of the container, for example by pipette or syringe. The container is then placed on the rotating device and is self-supporting while being rotated about its vertical axis. It is believed that, during such rotation, the red blood cells are caused to migrate outwardly by centrifugal force and up the inclined surface provided by the inverted conical bottom wall of the chamber. The cells then migrate outwardly and downwardly through the passageway and into the outer annular chamber, leaving clear plasma in the central chamber. In experiments, it has been found that a clear plasma sample can be obtained in the order of 30 seconds.
It is believed that the inverted conical shape of the bottom wall of the central chamber is important in promoting migration of the red blood cells towards the outer chamber. At the same time, the location and orientation of the passageway inhibits return of the red cells and remixing with the plasma and central chamber after rotation has ceased.
In order that the invention may be more clearly understood, reference will now be made to the accompanying drawings which illustrate particular preferred embodiments of the invention by way of example, and in which:
FIG. 1 is a perspective view from above of a plasma separator in accordance with the invention;
FIG. 2 is a vertical sectional view through the central axis of the separator shown in FIG. 1, with the separator shown mounted on a device for rotating the separator;
FIG. 3 is a view similar to FIG. 2 illustrating removal of a separated plasma sample from the central chamber of the separator; and,
FIG. 4 is a view similar to FIG. 2 (but without the rotary device) illustrating an alternative embodiment of the invention.
Referring now to the drawings, FIG. 1 shows the external appearance of the plasma separator provided by the invention, as seen from above. In this embodiment, the separator is made in one piece in a semi-rigid plastic material, for example by blow-moulding. In an alternative embodiment, however, the separator could be made in two or more parts.
The separator itself is generally denoted by reference numeral 20 and essentially comprises a container which is symmetrical about a normally vertical axis 22. The container is designed so that it can be coupled to a device that is capable of rotating the container at high speed about axis 22. In FIG. 2, part of such a device is shown supporting the separator. The device comprises a platform 24 having a recess 26 into which the separator is frictionally engaged. The platform 24 is carried by a vertical shaft 28 that is connected to a drive motor (not shown) for rotating the shaft and with it the separator at high speed. The structure surrounding the platform 24 is indicated at 30.
The container is designed to be self-supporting during rotation and, to this end, is made of a semi-rigid plastic material as noted previously. The container defines internally a central chamber 32 for receiving a blood sample, and an annular outer chamber 34 for receiving red blood cells separated out of the blood sample by rotation of the container about axis 22. An annular passageway 36 connects the two chambers 32 and 34.
The central chamber 32 has a lower wall 38 of inverted conical shape extending to a circular edge 40 at an upper end of wall 38 and at the inner end of passageway 36. The passageway extends downwardly and outwardly from edge 40 to the outer chamber 34, which chamber is located at the outer end of the passageway and below the circular edge 40. The container has a single opening 42 located in a top wall 44 above the central chamber for permitting insertion of a blood sample into and removable of plasma from the chamber.
In practice, a blood sample will typically be introduced into the central chamber 32 through opening 42 by means of a pipette. Preferably, the central chamber will be filled to the level of edge 40 as indicated by the level line "1" in FIG. 2. The container will be frictionally retained in the recess 26 in platform 24 sufficiently tightly that the container will stay in place when the platform is rotated at high speed. At this time, red cells in the blood sample will tend to migrate up the inclined inner surface of wall 38 as shown generally at 46a in FIG. 2, over edge 40 as indicated at 46a and down the passageway 36 into chamber 34.
Preferably, the plasma separator will be made of a transparent or transluscent plastic material so that the sample can be visually observed during rotation of the separator. The person operating the device on which the separator is rotated can then stop rotation when substantially all of the red cells appear to have migrated into the outer chamber 34.
FIG. 3 shows the plasma separator after it has been removed from platform 24 when separation has been completed. Clear plasma indicated by reference numeral 48 remains in the central chamber 32 while the outer chamber 34 contains red blood cells indicated at 50. The stem of a pipette is shown at 52 as having been inserted through opening 42 for withdrawing the plasma sample from chamber 32. Normally, the red blood cells 50 would not be required for analysis and would be simply discarded. It is anticipated that the separator will be disposable so that it can be simply thrown away after the plasma has been removed from chamber 32. On the other hand, if it is desired to either retrieve the red cells or reuse the separator, then the red cells can be transferred into the central chamber by appropriately tipping the separator and the red cells can then be removed by pipette.
From a comparison of FIGS. 2 and 3 it will be noted that the walls of the container that define the passageway 36 are shown spaced apart somewhat in FIG. 2 but in contact in FIG. 3. Thus, the container is designed so that the walls that define passageway 36 will tend to move apart under centrifugal force to allow liquid flow through passageway 36 during rotation of the separator, but will close to in effect isolate the red cells from the plasma sample when the separator is stationary. Referring specifically to FIG. 2, the container has a wall 54 at the inner side of passageway 36 that remains relatively stationary under the effects of centrifugal force due to the bracing effect of the inverted conical wall 38. The wall 56 at the outer side of passageway 36 on the other hand is designed to be more flexible and to move away from wall 54 under the effect of centrifugal force.
FIG. 4 shows an alternative embodiment of the invention in which primed reference numerals have been used to denote parts corresponding to parts shown in the previous views. In this case, the container forming the separator is essentially the same as the container shown in the previous views except in that an outlet for plasma is provided at the centre of the bottom wall 38 of chamber 32. In FIG. 4, the outlet is denoted by reference numeral 58 and is surrounded by a short neck 60 over which is frictionally fitted an inverted cap 62 that acts as a collection chamber for the plasma. In this embodiment, when the separation of plasma from red blood cells has been completed, all that need be done is to remove the cap 62, containing the plasma. The step of inserting a pipette to remove the plasma is unnecessary. Opening 42' is still provided in the top wall 44 of the container for the purpose of introducing a blood sample into the container. The sample would be introduced at a location off axis 22' while the separator is rotating. Alternatively, cap 62 may be provided with a plug for outlet 58 as indicated in ghost outline at 64 in FIG. 4.
The device used to rotate the plasma separator need not be a high quality laboratory-standard centrifuge as is required in the prior art, although such a device could undoubtedly be used for this purpose. All that is required is a drive means that is capable of engaging and rotating the separator at relatively high speed. It should also be noted that the separator is self-supporting during rotation and that it is unnecessary to confine the separator within some sort of rotor structure as in the prior art.
In summary, the device provided by the invention provides ah extremely simple and inexpensive means for separating plasma from a blood sample, quickly and efficiently. Numerous other advantages are also provided by the device. For example, in terms of safety, no handling of the blood sample is required. The separator can be made of a plastic material so that there is no glass that might break. At the same time, the separator can be made transparent so that the blood separation action is visible and the separator can be made relatively inexpensively so that it can be disposable. Unlike blood separation techniques performed using a centrifuge, balancing of the rotary device is not a concern. Also, aerosoling of the sample is minimized because the sample is substantially closed by the separator.
Other advantages are that the separator can be used to "harvest" plasma by adding one blood sample after another to a large size separator.
The separators can also be made stackable so that multiple units can be stacked on the same spinner.
It will of course be understood that the preceding description relates to particular preferred embodiments of the invention only and that the invention is not limited to these embodiments.
|Cited Patent
|Filing date
|Publication date
|May 7, 1962
|Mar 8, 1966
|Hein George N
|Centrifuge and centrifuge head for separating constituents of a liquid and a liner therefor
|May 22, 1968
|Dec 23, 1969
|Engel Lewis O
|Centrifuge apparatus with flexible boot
|Jun 15, 1977
|Sep 5, 1978
|Beckman Instruments, Inc.
|Multi-compartment centrifuge rotor liner
|Jan 27, 1978
|Mar 6, 1979
|Beckman Instruments, Inc.
|Chylomicron rotor
|Sep 29, 1977
|Dec 11, 1979
|Beckman Instruments, Inc.
|One piece chylomicron rotor liner
|Aug 9, 1982
|Jul 10, 1984
|Instrumentation Laboratory, Inc.
|Reagent storage vessel
|Citing Patent
|Filing date
|Publication date
|Aug 2, 1991
|Feb 23, 1993
|Jean Guigan
|Apparatus for separating two phases of a sample of heterogeneous liquid by centrifuging, the apparatus being particularly suitable for separating plasma from whole blood
|Jul 21, 2000
|May 29, 2001
|The Board Of Trustees Of The Leland Stanford Junior University
|Oct 21, 1998
|Aug 14, 2001
|The Board Of Trustees Of The Leland Stanford Junior University
|Method for simultaneous centrifugation of samples
|Apr 9, 2001
|Jun 17, 2003
|Medtronic, Inc.
|Centrifuge bag and methods of use
|Apr 9, 2001
|Jun 24, 2003
|Medtronic, Inc.
|Centrifuge container having curved linear shape
|Apr 9, 2001
|Jul 22, 2003
|Medtronic, Inc.
|Hard shell disposable reservoir having complex internal design for use in a centrifuge
|Apr 9, 2001
|Aug 26, 2003
|Medtronic, Inc.
|Method for handling blood sample to ensure blood components are isolated
|Mar 26, 2001
|Nov 25, 2003
|The Board Of Trustees Of The Leland Stanford Junior University
|Method of simultaneous mixing of samples
|Apr 9, 2001
|Dec 28, 2004
|Medtronic, Inc.
|Clam shell blood reservoir holder with index line
|Aug 18, 2003
|Mar 15, 2005
|Byk Gulden Italia S.P.A.
|Automatic diagnostic apparatus
|Sep 3, 2003
|May 1, 2007
|Therakos, Inc.
|Apparatus for the continuous separation of biological fluids into components and method of using same
|Dec 3, 2004
|Dec 11, 2007
|Medtronic, Inc.
|Flexible centrifuge bag and methods of use
|Dec 3, 2004
|Mar 25, 2008
|Ateriocyte Medical Systems, Inc.
|Blood centrifuge having clamshell blood reservoir holder with index line
|Dec 15, 2005
|Jan 13, 2009
|Therakos, Inc.
|Method and apparatus for collecting a blood component and performing a photopheresis treatment
|Sep 3, 2003
|Jan 20, 2009
|Therakos, Inc.
|Method for collecting a desired blood component and performing a photopheresis treatment
|Apr 19, 2006
|Mar 17, 2009
|Dennis Briggs
|Apparatus for the continuous separation of biological fluids into components and method of using same
|Dec 19, 2006
|Dec 14, 2010
|Therakos, Inc.
|Method for collecting a desired blood component and performing a photopheresis treatment
|Mar 1, 2011
|Arteriocyte Medical Systems, Inc.
|Centrifuge container and methods of use
|Apr 19, 2006
|Mar 29, 2011
|Therakos, Inc.
|Apparatus for the continuous separation of biological fluids into components and method of using same
|May 22, 2008
|May 24, 2011
|Statspin, Inc.
|Centrifugal device and method for fluid component separation
|Nov 27, 2012
|Kensey Nash Corporation
|Centrifuge method and apparatus
|Apr 13, 2012
|Mar 12, 2013
|Kensey Nash Corporation
|Aug 12, 2011
|Jun 25, 2013
|Kensey Nash Corporation
|Aug 7, 2012
|Jul 16, 2013
|Kensey Nash Corporation
|Systems and methods for separating constituents of biologic liquid mixtures
|Feb 15, 2012
|Oct 15, 2013
|Kensey Nash Corporation
|Feb 18, 2013
|Oct 22, 2013
|Kensey Nash Corporation
|Methods for separating constituents of biologic liquid mixtures
|Mar 18, 2013
|Dec 31, 2013
|Kensey Nash Corporation
|Methods for separating constituents of biologic liquid mixtures
|Oct 18, 2013
|Jun 10, 2014
|Kensey Nash Corporation
|Methods for separating constituents of biologic liquid mixtures
|Oct 11, 2013
|Jun 24, 2014
|Kensey Nash Corporation
|Feb 13, 2013
|Oct 28, 2014
|Kensey Nash Corporation
|Jun 3, 2014
|Mar 10, 2015
|Kensey Nash Corporation
|Jun 19, 2014
|Aug 25, 2015
|Kensey Nash Corporation
|Jun 7, 2010
|Jan 19, 2016
|Therakos, Inc.
|Method for collecting a desired blood component and performing a photopheresis treatment
|Apr 9, 2001
|Jan 22, 2004
|Dolecek Victor D.
|Clam shell blood reservoir holder with index line
|Aug 18, 2003
|Jun 10, 2004
|Byk Gulden Italia S.P.A.
|Automatic diagnostic apparatus
|Dec 3, 2004
|Apr 21, 2005
|Medtronic, Inc.
|Blood centrifuge having clamshell blood reservoir holder with index line
|Dec 3, 2004
|May 12, 2005
|Medtronic, Inc.
|Flexible centrifuge bag and methods of use
|Dec 10, 2007
|Jul 17, 2008
|Arteriocyte Medical Systems, Inc.
|Flexible centrifuge bag and methods of use
|Nov 26, 2009
|Statspin, Inc. D/B/A Iris Sample Processing
|Centrifugal device and method for fluid component separation
|Dec 3, 2009
|Arteriocyte Medical Systems
|Flexible centrifuge bag and methods of use
|May 21, 2009
|Dec 3, 2009
|Arteriocyte Medical Systems
|Flexible centrifuge bag and methods of use
|Mar 25, 2014
|Nov 11, 2015
|Centrifugal separation container, centrifugal separation device, and centrifugal separation method using said container and device
|Mar 25, 2014
|Aug 24, 2016
|Jul 29, 1991
|Feb 5, 1992
|GUIGAN, Anne
|Device for centrifugally separating two phases of a heterogeneous liquid, in particular for use in the separation of blood plasma
|May 21, 2009
|Nov 26, 2009
|Statspin, Inc.
|Centrifugal device and method for fluid component separation
|U.S. Classification
|494/38, 494/45, 494/24, 494/44
|International Classification
|Cooperative Classification
|European Classification
|Feb 8, 1993
|Fee payment
Year of fee payment: 4
|Jun 10, 1993
Owner name: 1017670 ONTARIO INC., CANADA
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:CANADIAN MEDICAL LABORATORIES LIMITED;REEL/FRAME:006554/0655
Effective date: 19930312
|Feb 10, 1997
|Fee payment
Year of fee payment: 8
|Feb 27, 2001
|Maintenance fee reminder mailed
|Aug 8, 2001
|Surcharge for late payment
Year of fee payment: 11
|Aug 8, 2001
|Fee payment
Year of fee payment: 12


text:
Since 1947 Town + Country Cedar Homes has focused on providing high quality Luxury Log and Timber homes to families and discerning home owners in every state in the US and many countries across the globe. We believe strongly in keeping the traditions and quality of years past and combining them with modern technologies and techniques, green building practices and most importantly integrity.
As an experienced design/build team we seek to listen and observe before creating the luxury that is particular to each home, owner and environment, while avoiding the stigma and inflated prices often associated with "custom luxury". From our design and construction facility in northern Michigan we service most areas of the US. We have remained a small enough custom luxury log home builder to give your project the attention it deserves, yet we are large enough to get the best service and pricing from subcontractors and suppliers.
We act as both your partner and advocate during every phase of design and construction. And while we always keep you informed about important issues as they arise, we also pride ourselves on making the entire process more relaxing and enjoyable.
We strive to work by the motto "How will my actions of today make my client feel tomorrow?"
I can't thank you enough for taking time out of your Sunday to 'draw' the layout of the home in the snow. I could totally feel every room. I can't wait to get started!~ Claire E.
Town + Country Cedar Homes is well known across the country for innovative custom log home designs, timber style home designs, cottage designs – all manner of natural wood home architecture. We are a log home builder like none other. But, as with all things beautiful, there must be substance.
The most dependable, durable and beautiful wood for log homes.
Meet our Director of Client Fulfillment in this episode of EPIC LOG HOMES
Quality and consistency straight from our Boyne Falls, MI mill.


text:
Use Your Brain to Change Your Age
Secrets to Look, Feel, and Think Younger Every Day
by Daniel G. Amen, M.D.
- #9 in Nonfiction, Health & Well Being, Health, Aging
- #524 in Nonfiction, Health & Well Being, Self Help
- #38 in Nonfiction, Health & Well Being, Health, Healthy Living
Get eBook
- Your price$11.99
You'll see how many points you'll earn before checking out. We'll award them after completing your purchase.
A healthy brain is the key to staying vibrant and alive for a long time, and in Use Your Brain to Change Your Age, bestselling author and brain expert Dr. Daniel G. Amen shares ten simple steps to boost your brain to help you
live longer, look younger, and dramatically decrease your risk for Alzheimer's disease.
Over the last twenty years at Amen Clinics, Dr. Amen has performed more than 70,000 brain scans on patients from ninety different countries. His brain imaging work has taught
him that our brains typically become less active with age and we become more vulnerable to
memory problems and depression. Yet, one of the most exciting lessons he has learned is that
with a little forethought and a brain-smart plan, you can slow, or even reverse, the aging process in the brain.
Based on the approach that has helped thousands of people at Amen Clinics along with the most cutting-edge research, Dr. Amen's breakthrough, easy-to-follow antiaging program shows you how to:
• Boost your memory, mood, attention,
and energy
• Decrease your risk for Alzheimer's and
other forms of dementia
• Eat to live longer
• Reduce the outward signs of aging and
make your skin more beautiful
• Promote the healing of brain damage due
to injury, strokes, substance abuse, and
toxic exposure
• Dramatically increase your chances of
living longer and looking younger
••And much more.
By adopting the brain healthy strategies detailed in Use Your Brain to Change Your Age, you can outsmart your genes, put the brakes on aging, and even reverse the aging process. If you change your brain, you can change your life—and your age.
People who read this also enjoyed
Ratings and Reviews
Overall rating
Share your thoughts
You've already shared your review for this item. Thanks!
We are currently reviewing your submission. Thanks!
All Reviews
- Filter by
- All 0
- 5 Stars 5
- 4 Stars 4
- 3 Stars 3
- 2 Stars 2
- 1 Star 1
- Sort By
- Most Helpful 0
- Newest 3
- Oldest 4
- Highest Rated 1
- Lowest Rated 5
0 person found this review helpful
0 people found this review helpful
0 of 0 people found this review helpful
Was this helpful to you?
Thanks for your feedback!Report as inappropriate
Discovery your brain
This book helps me to understand, so much about my brain, and how it really works. Most people know they have a brain, but never quite understand the it's function. This book give a better insite, better understanding and better knowledge for those who want to understand more about their brain snd it's function. Thanks, again for the informationby Smithy on March 22, 2015
Use Your Brain to Change Your Age
by Daniel G. Amen, M.D.
Share your thoughts
Tell readers what you thought by rating and reviewing this book.
Rate it *
Please make sure to choose a rating
Add a review* Required
Review *
How to write a great review
- Say what you liked best and least
- Describe the author's style
- Explain the rating you gave
- Use rude and profane language
- Include any personal information
- Mention spoilers or the book's price
- Recap the plot
(0) 50 characters minimum
The review must be at least 50 characters long.
Title *
The title should be at least 4 characters long.
Display Name *
Your display name should be at least 2 characters long.
Report a review
At Kobo, we try to ensure that published reviews do not contain rude or profane language, spoilers, or any of our reviewer's personal information.
Would you like us to take another look at this review?
You've successfully reported this review. We appreciate your feedback.
Use Your Brain to Change Your Age
by Daniel G. Amen, M.D.
Thanks for Sharing!
You submitted the following rating and review. We'll publish them on our site once we've reviewed them.
by on October 26, 2016
eBook Details
- Potter/TenSpeed/Harmony, February 2012
- Imprint:
- 9780307888563
- Language:
- English
- Download options:
- EPUB 2 (Adobe DRM)
You can read this item using any of the following Kobo apps and devices:


text:
- Aa
- Aa
Bengson, John 2015. A Noetic Theory of Understanding and Intuition as Sense-Maker. Inquiry, Vol. 58, Issue. 7-8, p. 633.
Stratton-Lake, Philip 2013. International Encyclopedia of Ethics.
2000. A Psychological Approach to Ethical Reality.
Geiger, Gebhard 1995. Why are there no objective values?. Journal for General Philosophy of Science, Vol. 26, Issue. 1, p. 35.
Shweder, Richard A. and Haidt, Jonathan 1993. THE FUTURE OF MORAL PSYCHOLOGY:. Truth, Intuition, and the Pluralist Way. Psychological Science, Vol. 4, Issue. 6, p. 360.
WALLER, BRUCE 1984. Purposes, Conditioning, and Skinner's Moral Theory: Comments on Mills' Observations. Journal for the Theory of Social Behaviour, Vol. 14, Issue. 3, p. 355.
North.—What is the trouble about moral facts? When someone denies that there is an objective moral order, or asserts that ethical propositions are pseudo-propositions, cannot I refute him (rather as Moore refuted those who denied the existence of the external world) by saying: "You know very well that Brown did wrong in beating his wife. You know very well that you ought to keep promises. You know very well that human affection is good and cruelty bad, that many actions are wrong and some are right"?
West.—Isn't the trouble about moral facts another case of trouble about knowing, about learning? We find out facts about the external world by looking and listening; about ourselves, by feeling; about other people, by looking and listening and feeling. When this is noticed, there arises a wish to say that the facts are what is seen, what is heard, what is felt; and, consequently, that moral facts fall into one of these classes. So those who have denied that there are "objective moral characteristics" have not wanted to deny that Brown's action was wrong or that keeping promises is right.
Email your librarian or administrator to recommend adding this journal to your organisation's collection.


text:
I endorse Billy. He is a highly skilled attorney that is well respected in the legal community.
Michael Waddington Military law Attorney
Relationship: Fellow lawyer in community
Mr. Hicks not only answered his own phone, but immediately did a little research on a matter which was out of our jurisdiction. We were very impressed with his willingness to help at short notice. He seemed to have a great handle on the workings of the court system in El Paso and the judge on this case.
Ronee Steiner Divorce and separation Attorney
Relationship: Other
I endorse this lawyer.
Priscilla Bush Criminal defense Attorney
Relationship: Co-worker
I highly endorse Judge Hicks - he is a great trial attorney, and was also a great judge on the bench.
Merwan Bhatti Business Attorney
Relationship: Fellow lawyer in community
Help your colleagues,
build your professional network,
and increase your exposure.
Note: If you are a current or former client of this lawyer, tell others what it's like to work with him or her (anonymously, if you want). Your post will make a difference. Review this lawyer.


text:
you are viewing a single comment's thread.
DCIX has been paying less than a year- I would suggest strong companies with good dividend histor; there are hundreds. Its always a gamble with small companies without any earnings or dividend history. Dividend investing isn't supposed to be a gamble- Its close to a sure thing. I currently own 35 dividend paying companies; average yield approx. 6%. The key- buy them during market corrections at or near yearly low prices.


text: 3bdrm.2bath waterfront ranch, all remodeled since 2009,, ground up rehab, really only thing orig is the foundation, structure, interior, mechanicals, kitchen, baths, plumbing, heating, a/c, roof, windows, floor deck all new, 2006 new 2 car det. garage w/ 750 sq.ft guest apartment, w/sep. kitchen, wood stove, patio, separate utils for guest house refrigerator and microwave, new carpets, shed, professional landscaped! Best lakeside opportunity in the area Listing Courtesy of MARK F. PICCARRETO ,Central MLS


text:
John Varvatos Star USA
'Barrett' Plain Toe Boot (Men) (Online Only)
Free ShippingItem #553575
ShowUnavailable at stores near you.
Your selection isn't available in stores near you. Try a new location:
Show stores within of
HideDetails & Care
Weathered goatskin shapes a smart boot with uniquely designed lacing and a convenient side zipper for easy entry.
- Goatskin leather upper/calfskin lining/rubber sole.
- By John Varvatos Star USA; imported.
- Men's Shoes.
ShowShipping & Returns
Gift Options
Select a size to see if gift options are available for this item.
Same-day Delivery
Same-Day Delivery isn't currently available to your default shipping address, but other expedited shipping methods are available at Checkout.
Show eligible zip codes and details.
'Barrett' Plain Toe Boot (Men) (Online Only)
Write a Review0 Reviews


text:
Average Rating
User Reviews
Blue Exorcist Review - 4.5 StarsBlue Exorcist has a very interesting story and many events to grab your attention, you won't find yourself bored too often when watching this. There are likable characters along with some dis-likable, though it depends your tastes.This anime really gives you what you want in the action aspect and has a really well-done plot too along with some backstories.Read more
Overall I think Blue Exorcist is a ...
Wonderful anime, would recommend.I liked most things about Blue Exorcist. The characters, the plot, the idea of the story, and so on. The only thing I didn't like about it was that it rushed a lot of the stuff, such as Rin's development. It could also use some more connected episodes, rather then making them one event and disconnected, scattered ones. But it brings more connection amongst the characters, which is good. They ...Read more
Needs second season!There should be a second season in which Rin becomes paladin and Yukio learns to use his new found powers. Then eventually Yukio becomes the new principal of that school. Also, Rin's friends become the best team in history, including himself. Then they ACTUALLY defeat Satan.
Extremeness which must be loved...Oh, this was highly entertaining to me, though it may be somewhat blasphemous, how could it not be enjoyed? These are the things I enjoy the most, over the top humor, good fights, and an array of characters you can't help but come to love, even those you probably should not.
0 out of 1 people found this review helpful:blue exorcist season 2is there going to be a second season for this show????? i really hope there is. this show is so funny. i love rin and yukio. go a bit emotional when shiro died. i was like crying and say i knew it i knew he was going to die. i was so sad when shiro died like wooah.
Why do you leave me with so little!?Blue Exorcist was a show I watched a long time ago, but did thoroughly enjoy. Don't get me wrong, I loved the characters and even the plot (though some episodes flat out didn't fit) but it just ended so quickly and abruptly. But let me get to this in a second.Read more
The main character Rin is very unique in his design, but not how he is displayed. On the surface, you could just blow him off as just a ...
0 out of 1 people found this review helpful:season 2????????????????????THERE HAS TO BE A SEASON TWO!!!!! There are so many things that unfinished, like what happens to everyone, what happens to true cross academy now Yukio has the blue flames too. Will the class treat Mr. Okumura now that he has the blue flames.
Watch this and watch the adorable movie too!This anime is the perfect balance of serious and not-so-serious. I would recommend it to fans of Japanese culture and folklore, as well as anybody who likes fairy tales considering the author loosely based the storyline on a Brothers Grimm tale. It follows the son of the devil, so there are some biblical references if you dare to catch onto them, exorcisms, popular depictions of youkai, exciting ...Read more
Different Take on the Exorcising StoryI had watched Ghost Hunt and Tokyo Raven from Funimation before I watched this so I was in the mood for the whole exorcising spirits and demons thing. When I found this on here, I just had to watch this series. This was unique to me because the main character turns out to be the son of the devil and he is vanquishing spirits and demons. Really different for me with this type of thing.Read more
Plot - ...


text:
Add to this Profile
- Primary Role
- VP of Marketing @ Compendium
- Born:
- March 9, 1983
- Gender:
- Male
- Location:
- Unknown
- Website:
- http://chris-moody.com
- Social:
Person DetailsUpdate
Chris Moody is VP of Marketing at Compendium and lives in Raleigh, NC. His work has been covered by Mashable, Social Fresh, Marketing Profs, Pragmatic Marketing, The Executive's Guide to Enterprise Social Media (Wiley) and more.
Chris blogs at chris-moody.com. He is frequently seen guest lecturing at local universities and discussing social media and new marketing methods. Chris received his MBA from North Carolina State University, along with a BS in Business Management. In addition to his passion for promoting Compendium and participating in social media events and education, Chris also enjoys playing basketball and softball in his spare time.
Specialties:Branding and identity, interactive marketing, digital marketing, blogging, taking products to market, marketing strategy, content marketing, product development, project management, marketing director, business development, social marketing, director of marketing, social media, compendium, left field, third base, being a "glue" guy on the basketball court
Jobs (5)Update
VP of Marketing
Aug, 2013 - Current (about 3 years)
Education (1)Update
Robert Gordon University
MBA, Supply Chain Management2007
News (6)Update
|Sep 16, 2015
|TechCrunch - Twitter And Bloomberg Expand Partnership To Bring More Data To Terminal Users
|Sep 16, 2015
|Bloomberg - Bloomberg and Twitter Sign Data Licensing Agreement
|Jul 29, 2015
|Financial Times - Jack Dorsey says he will spare no sacred cows at Twitter - FT.com
|Jul 27, 2015
|Bloomberg - As Donald Trump Rises, Republicans Do Outlandish Things to Get Attention
|Jun 22, 2015
|Venture Beat - Lightning strikes vs. the sun: Twitter's advertising challenge in one chart
|Jan 17, 2011
|socialwayne.com - Social Media Pro to Watch in 2010


text:
Pre-order now. Dispatches in 15-20 days*. Conditions Apply*
This product dispatches in 8-10 business days*. Conditions Apply*
Order today with Bajaao Express, and your product will dispatch in 24 hours
Special Import. Usually dispatches in 12-15 Days. Conditions Apply*
Special import. Dispatches in 5-8 days from International Warehouse. Conditions Apply*
EMI starts from Rs. 362.92.
Click here for options.
Sennheiser NB2-BEI Headset for Lavalier Microphones is designed for the unobtrusive attachment of MKE 2 or ME 102/104 clip-on microphones. The microphone cable is easily inserted into the flexible construction of the adapter. The headmic adapter together with the clip-on microphone make an almost invisible head-worn microphone which gives complete freedom of movement in any application where you need both hands free. The cables connect into the construction of the headband to avoid access cable runs and the flexible design ensures a firm, comfortable fit.
Sennheiser NB2-BEI Features:
Collections: Accessories Store, Amazing New Deals | Save Upto 50%, BAJAAO's Most Wanted! Special Discounts on bestsellers!, Dispatches in 8 - 10 Days, Everything Under ₹9,999, Exclude Out-of-stock, Feed: Topsellers, Guitar Keyboard Accessories, Mega Discount, Midnight Discount, Rakshabandhan Sale - GIFTS FROM BROTHER TO SISTER, Sennheiser, Shop by, Special Deals, Super Savings on Sennheiser: The best from the industry at the best price!, ₹5,000 to ₹10,000
Sign up for access to exclusive deals, special offers and more …
© 2016 BAJAAO.COM. BAJAO | BAJAAO Music Private Limited


text:
Horizon Pharma, Inc. (NASDAQ:HZNP)
Q3 2012 Earnings Conference Call
November 13, 2012, 08:00 AM ET
Timothy P. Walbert – President, Chairman and CEO
Robert J. De Vaere – Executive Vice President and CFO
Todd N. Smith – Executive Vice President and CCO
Lisa Bayko - JMP Securities
Daniel Chang - Stifel Nicolaus
Good morning everyone and welcome to the Horizon Pharma Third Quarter 2012 Financial Results Conference Call. This call is being recorded. At this time for opening remarks and introduction, I would like to turn the call over to Horizon Pharma's Chief Financial Officer, Mr. Bob De Vaere. Mr. De Vaere, Please go ahead sir.
Robert De Vaere
Thank you. Good morning, and welcome to Horizon Pharma's third quarter earnings call. This morning we issued a press release that provides the details of the company's financial results for the third quarter ended September 30, 2012, as well as an update on DUEXIS and RAYOS and other recent business highlights. This press release is available on our website at www.HorizonPharma.com.
Leading the call today will be Tim Walbert, Chairman and President and Chief Executive Officer of Horizon Pharma. Tim will provide a corporate update. Todd Smith, Executive Vice President and Chief Commercial Officer will provide an overview on the commercial launch of DUEXIS and prelaunch activities for RAYOS. And I will provide an overview of the financial highlights from the third quarter before turning the call back over to Tim for closing remarks.
As a reminder during today's call, we will be making certain forward-looking statements. These statements may include statements regarding our financial outlook, our sales and marketing plans, potential growth of our business and plans to enter into future commercial agreement. These forward-looking statements are based on current information, assumptions, and expectations that are subject to change and involve a number of risks and uncertainties that may cause actual results to differ materially from those contained in the forward-looking statements. These risks are described in our filings made with the Securities and Exchange Commission including our Annual Report on Form 10-K for the year ended December 31, 2011 and subsequent quarterly reports on Form-10-Q. You are cautioned not to place undue reliance on these forward-looking statements and Horizon disclaims any obligations to update such statements. Further, we may also discuss non-GAAP financial measures during this call to help you understand our underlying business performance. The GAAP reconciliations are provided in our press release which was posted on our corporate website www.HorizonPharma.com.
I will now turn the call over to Tim.
Tim Walbert
Thank you Bob, and thank you to everyone for joining us on the call today. Horizon has continued to make substantial progress since our last call. And today I will summarize the recent developments in our business, particularly with the promotion of DUEXIS in the U.S. U.S.FDA approval of RAYOS in a broad range of indications, and securing approximately $81 million in a public follow-on offering in June.
The capital raise during third quarter further strengthens our financial position and allows us to focus our efforts on the ongoing commercialization of DUEXIS and the launch of RAYOS in the U.S. We expect that this recent offering along with our existing cash resources will fund our operations through 2013.
We are pleased with the third quarter performance of DUEXIS which showed a steady increase in sales and prescription demand. This increase was driven primarily by our 80 sales representatives, who only covered about 10,000 physicians who collectively represented about 8% of the NSAID market prescriptions in the U.S.
DUEXIS net sales for the third quarter were $2.6 million, an increase of 63% versus second quarter of 2012. According to monthly data from Source Healthcare Analytics formerly Wolters Kluwer, total prescriptions in the third quarter of 2012 for DUEXIS were over 25,000, an increase of 33% versus the second quarter of 2012. Total DUEXIS monthly prescriptions for the month of September were 9,282, an increase of 10% versus August 2012 and an increase of 33% versus August 2012, when normalizing for selling days per month. Also, at the end of September, more than 6,500 physicians have written prescriptions for DUEXIS since we launched the product.
Although, we had strong sequential DUEXIS growth in the third quarter, we did not have the critical mass of DUEXIS promotions to drive revenue growth needed to meet our long term goals. As a result, we underwent a planned significant expansion of our sales force in the third quarter and completed co-promotion agreement with Mallinckrodt, the pharmaceutical business of Covidien. In late September, we completed our sales force expansion increasing from 80 to approximately a 150 representatives. This expansion along with our co-promotion agreement with Mallinckrodt allows us to significantly increase our reach and frequency of promotion for DUEXIS.
Our strategy is for our 150 sales representatives to call in 25,000 high value NSAID prescribers and for Mallinckrodt to promote DUEXIS to another 25,000 exclusive physician targets. We believe that Mallinckrodt's expertise in the distribution of pain therapeutics along with their experienced sales force in the osteoarthritis and pain markets is well suited to successfully market DUEXIS to their exclusive target.
As a result of our combined promotional effort on October 1, we increased to call on physician targets for DUEXIS five-fold from 10,000 to 50,000. These 50,000 targets now make up over 50% of the NSAID prescription market which we feel is a critical mass needed to drive DUEXIS revenues moving forward. As a reminder, we will record all revenues for DUEXIS under the Mallinckrodt agreement and will remain responsible for DUEXIS manufacturing, supply, and regulatory activities while Mallinckrodt will receive compensation based on prescriptions generated by their sales efforts against their exclusive targets, which we will record in sales and marketing expenses.
I would now like to discuss early results of our expanded efforts since October 1. In the week ending October 26, we hit a new all time weekly prescription high of 2,884 prescriptions for DUEXIS, an increase of 6.1% over the prior week and 4 weeks sequential total prescription growth of approximately 20% and new prescription growth of 23%. I would like to note we expect prescriptions to temporarily go down for the week ending November 2 due to the devastating effect of Sandy in many East Coast states.
Now, I would like to provide an update on RAYOS. RAYOS was approved on July 26 with a broader range of indications than we anticipated allowing for potential sales on a wide range of inflammatory diseases. In addition to rheumatoid arthritis and polymyalgia rheumatica RAYOS is approved for the treatment of 79 incremental indications including psoriatic arthritis, ankylosing spondylitis, asthma and chronic obstructive pulmonary disease. Our primary efforts during the launch will focus on rheumatologic diseases such as rheumatoid arthritis and polymyalgia rheumatica, but given this broad range of approved indications we are working to develop a broader commercial strategy to expand the opportunity for RAYOS in key IL-6 mediated diseases such as asthma and COPD.
Yesterday, we initiated promotion of RAYOS for rheumatoid arthritis, polymyalgia rheumatica and other rheumatologic diseases to rheumatologists attending the American College of Rheumatology Annual Meeting in Washington DC. This meeting typically attracts approximately 14,000 rheumatologists and other rheumatology healthcare professionals from around the world.
We estimate that approximately 60% to 70% of potentially U.S. rheumatology prescribers for RAYOS attend this meeting. Between now and late January 13, we'll be promoting RAYOS to over 1000 high value rheumatologists in the United States. In late January, we plan to launch RAYOS with our full sales force to the majority of the U.S. rheumatologists and key primary care physicians. In addition to our outreach to the rheumatologists during the ACR meeting, yesterday we hosted an investor briefing to discuss the approval and the initial launch of RAYOS with presentations from leading rheumatologists Dr. Maurizio Cutolo of the University of Genova and current president elect of EULAR, Dr. Frank Buttgereit of the Charité at the University of Berlin and lead investigator of the RAYOS phase III program, and Dr. Art Weaver of the University of Nebraska who's past president of the American College of Rheumatology. If you are unable to attend or view the meeting real time, I invite you to visit our website to access the presentations and listen to the webcast replay.
In addition to the promotional activities of RAYOS during the ACR Conference, there were two RAYOS abstracts presented during the meeting. Data presented by Dr. Rieke Alten Chief of Internal Medicine in Berlin concluded that based on the CAPRA II trial data of RAYOS, RAYOS helped treat RA patient's inflammation as well as improved patient's symptoms specifically the fatigue that many patients with RA experience. The second abstract of data from the CAPRA II study presented by Dr. Buttgereit demonstrated that morning stiffness duration, morning stiffness severity and pain intensity upon awakening correlated with disease activity score and helped assessment questionnaire disability index in all treatment group analyses.
In addition, patients who met ACR 20 response criteria, DAS 28 response criteria and the [HACC] [ph] disability index response criteria at a greater relative reduction of morning stiffness than patients who do not meet these criteria. Most importantly more patients treated with RAYOS met this response criteria than those in the controlled group. Outside the U.S RAYOS is known as LODOTRA and is approved in 19 countries.
LODOTRA's marketed in Europe through our distribution partner Mundipharma who also has commercial rights in certain Asia and Latin America country. Today, we reported third quarter net revenue of 3.9 million for LODOTRA and 9-month net revenue of 7.8 million. Before, I turn the call over to Todd, I would like to highlight developments we previously announced regarding our commitment to our intellectual property estate for both DUEXIS and RAYOS.
In September, we announced an important expansion of the DUEXIS patent estate with two additional notice of allowances from the U.S. Patent and Trademark Office, both entitled to stable compositions of famotidine and ibuprofen with claims covering DUEXIS tablets. In addition, we received the critical expansion of the patent estate for RAYOS. On October 15, we announced our collaborator SkyePharma received the notice of allowance from the U.S. Patent and Trademark Office entitled, 'The late release tablet with defined core geometry.'
These notice of allowances are significant step to closer to achieving our goals protect the commercial potential of DUEXIS up to 2028 and RAYOS out to 2024. At this point, I will turn the call over to Todd Smith, who will discuss our commercial highlights for the quarter.
Todd Smith
Thank you Tim. Good morning everyone and thank you for joining us today. Let me start by saying that as we expand our sales efforts and achieve the critical mass that Tim spoke about earlier in the call, we continue to make significant progress in executing an impactful launch for DUEXIS. While we are still in the early stage in the commercialization of DUEXIS, I'm pleased to share with you our recent progress.
According to monthly data from Source Healthcare Analytics through September 30, 2012 there have been approximately 55,000 total prescriptions for DUEXIS, since the launch, with over 25,000 in the third quarter alone, that's n increase to 33% versus the second quarter. As of September 30, there were 6500 cumulative devices prescribers, that's an increase of approximately 60% versus June 30, 2012. And our sales forces added over a 150 new prescribing health care professionals per week during the third quarter, and over 200 new prescribers per week in the month of September.
Further 45% of physicians we've detailed frequently which we define as more than 6 calls since we began calling on them have started prescribing DUEXIS. So, given this strong foundation of prescribers, our focus is turned to converting trail into adoption. And as a result, the number of physicians we have in adoption, which is any prescriber that is writing 5 or more DUEXIS scripts a week, has increased 86% since June 30, 2012.
So, in addition to that, our market research continues to show that approximately 85% of commercialized have access to DUEXIS with approximately 80% of DUEXIS commercial claims having a patient out of pocket cost of $25 or less. And this is due to the implementation of our co-pay assistance program.
As anticipated in any product launch we've identified areas in which we have increased our focus. Of late it is becoming common among pharmacies throughout the healthcare system in the United States is that pharmacists switching patients prescription to a generic or over-the-counter brands. This practice is a result of how pharmacies are incentivized. There is a concern because patients are not receiving the prescribed medication that their physicians intended.
Our sales representatives have begun to work closely with physicians and their staff to make them aware of this recent practice. So, we are addressing this in several ways. First, the profile of the representatives we hire has changed. We focused on hiring representatives with a successful business-to-business sales background versus those who have solely come from a pharma background. This is critical as we involve our promotional efforts from selling to physicians alone to selling to the entire office staff responsible for a patient getting a prescription. So our expanded sales team is aggressively focusing on this total office call.
Too often, a member of the office staff allows pharmacists to switch products without understanding why the physician wrote that product. Once a prescription is written, our representatives are focused on ensuring the office staff understands the benefits of DUEXIS and why they need to make sure patients get that prescription that doctor wrote.
In addition, we are piloting several programs to ensure patients have access to DUEXIS. One of them is an initiative to local and regional specialty pharmacies that allows DUEXIS to be shipped directly to the patient. Thereby ensuring patients get the prescription their doctor indented them to receive. We've piloted this strategy in several stage with encouraging initial results.
Lastly, I would like to speak briefly regarding our sales force expansion. As Tim mentioned, we now 150 representatives selling DUEXIS and soon to be selling RAYOS. With our sales force expansion and co-promotion agreement with Mallinckrodt, we believe we now have critical mass of DUEXIS promotion. We're now targeting over 50% of the non-steroidal prescriptions by calling on 50,000 targeted physicians. I'm encouraged by the initial feedback from our sales force and from the Covidien sales force. Physicians understand the benefits of DUEXIS and we think we now have the right sized combine sales up to drive significant growth. The most recent four week total prescription growth of DUEXIS through the week ending in October 26, was 20% with the four week new prescription growth of over 23%. With the RAYOS launch, our focus in now on top 15 leaders[ph] and prescribers of products to treat Rheumatologic diseases. We have 13 of our representatives launching RAYOS to over a 1000 Rheumatologists starting at the ACR meeting taking place this week.
From a messaging standpoint we're focused on the key benefit of RAYOS, which is the treatment of symptoms of RA and PMR which are at their worst in the morning. A pivotal trial on RA demonstrated statistically significant impact and both the primary endpoint of ACR 20 as well as the secondary endpoint of duration of morning stiffness. 94% of patients on RA therapy including standard prednisone still complain of morning symptoms with rheumatoid arthritis. Our goal is to position RAYOS as the rheumatoid arthritis therapy that allows patients to have less pain and stiffness in the morning and provide significant improvement in the quality of life. So, from a managed care standpoint, we've already had over 35 clinical presentations that managed care with positive relief feedback. We expect similar coverage of RAYOS as we have with DUEXIS in commercial payers. We also planned to ensure patients could access to RAYOS providing a plan to make sure that out of pocket expenses are manageable. Our goal is that patients averaged out of pocket cost will be below $25 per month. So, moving forward our broader sales effort remains focused on driving DUEXIS and we will launch RAYOS to majority of rheumatologists and our called on primary care physician in late January. Thank you for your time this morning and I will return the call over to Bob.
Robert De Vaere
Thanks Todd. First let me remind everyone that in December, the company began recognizing revenues from the sale of DUEXIS following its commercial launch in the U.S. DUEXIS has currently sold to wholesale pharmaceutical distributors and to several national and regional retail chains. Until the company can reliably estimate returns, the company is determined that shipment of products to wholesale distributors and retail chains do not meet the criteria for revenue recognition at the time of shipment. And we are currently deferring DUEXIS revenue recognition until the right of return no longer exists, which is the earlier of DUEXIS being dispensed through patient prescriptions or the expiration of the right of return. As of September 30, 2012 the company has 1.4 million in differed revenue on its balance sheet related to DUEXIS shipments. For the third quarter ending September 30, 2012, growth in net sales were 7.3 million and 6.5 million respectively compared to $0.3 million in both gross and net sales for the third quarter of 2011. DUEXIS gross sales were $3 million and net sales were $2.6 million after deducting trade discounts and allowances of $0.1 million and co-pay assistance costs of $0.3 million, and represented 41% of gross sales and 40% of net sales during the quarter ended September 30, 2012. Quarter-over-quarter growth in DUEXIS net sales was 63%.
LODOTRA gross sales were $4.3 million and net sales were $3.9 million after deducting trade discounts and allowances of $0.4 million during the quarter ended September 30, 2012.
Net loss for the quarter ended September 30, 2012, was $17 million, or $0.47 per share based on approximately 36 million weighted average shares outstanding, compared to a net loss of $17.2 million, or $1.30 per share based on 13.3 million weighted average shares outstanding, in the quarter ended September 30, 2011. The results for the third quarter ended September 30, 2012, include a one-time tax benefit of $4.3 million related to approval of RAYOS in July 2012. The approval resulted in a reclassification and amortization of certain intangible assets and an assessment of the company's deferred tax positions resulting in a reduction of current valuation allowances and recognition of a one-time net income tax benefit.
Non-GAAP net loss for the quarter ended September 30, 2012, was $13.9 million, or $0.39 per share, compared to a non-GAAP net loss of $15.6 million, or $1.18 per share, in the third quarter of 2011. Horizon provides non-GAAP financial measures, which it believes can enhance an overall understanding of Horizon's financial performance when considered together with GAAP figures. Please refer to the section of today's press release entitled "Note Regarding Use of Non-GAAP Financial Measures" for a full discussion on this subject.
Research and development expenses decreased $1.5 million, from $5.3 million during the three months ended September 30, 2011, to $3.8 million during the three months ended September 30, 2012. The decrease in research and development expenses during the current period was primarily associated with a $1.9 million reduction in regulatory submission fees and clinical trial expenses and a $0.3 million reduction in consulting fees, which was partially offset by a $0.7 million increase in salaries and benefits expense as a result of additional staffing and personnel expenses, primarily related to staffing the company's medical affairs group which supports scientific publications, health outcomes, medical education and information and medical communications.
Sales and marketing expenses during the current quarter increased $7.9 million, from $5.1 million during the three months ended September 30, 2011, to $13 million during the three months ended September 30, 2012. The increase in expense was primarily attributable to ongoing sales and promotional efforts related to the company's DUEXIS product launch and pre-launch activities of RAYOS, which included a $4.8 million increase in salaries and benefits expense associated with staffing of the company's sales and marketing functions, including the company's sales force expansion, a $2.1 million increase in market research and marketing programs and a $1 million increase in consulting and outside service costs.
General and administrative expenses increased $0.5 million, from $4.2 million during the three months ended September 30, 2011, to $4.7 million during the three months ended September 30, 2012. The increase in general and administrative expenses was primarily due to a $0.4 million increase in salaries and benefits expense associated with an increase in finance and administrative personnel and stock-based compensation expense, a $0.3 million increase in legal costs associated with intellectual property related matters and a $0.2 million increase in facility costs associated with higher rent and insurance costs, partially offset by a $0.4 million reduction in consulting expenses during the third quarter of 2012.
Interest expense increased $2.3 million during the 2012 period, from $1 million during the three months ended September 30, 2011, to $3.3 million during the three months ended September 30, 2012, primarily as a result of incremental interest expense associated with higher borrowing balances under the company's senior secured loan. After completing our equity offering late in the third quarter, the company had cash and cash equivalents of $121.3 million at September 30, 2012, which we expect will fund our operations through 2013.
Now, I would like to turn the call back over to Tim for some closing comments.
Timothy Walbert
Thank you, Bob. In summary, I believe we are well positioned to accelerate to excess revenue and launch real successively over the coming quarters. Initial prescription growth post our sales force expansion and the Mallinckrodt co-promotion DUEXIS is very encouraging.
Over the last year, we have established ourselves as a fully integrated commercial company with two new product launches and a strong balance sheet that has laid the groundwork to position the company for a success. From a broader corporate perspective, we continue to look to leverage our existing infrastructure. We are actively evaluating opportunities to co-promote, acquire or in-license additional products.
In the near term, our focus remains on successfully executing on the launch and commercialization of both DUEXIS and RAYOS. Thank you for joining us today, and at this time, we will open up the call for Q&A.
Question-And-Answer Session
(Operator Instructions) Our first question comes from Lisa Bayko of JMP Securities. Your line is open.
Lisa Bayko - JMP Securities
Hi, congratulations on your launch and on the quarter. I just want to ask about reimbursements for RAYOS. Can you maybe talk about any initial progress you have had, how conversations are going and how – what the patients will pay for when they get a prescription from you? Thanks.
Timothy Walbert
Hi Lisa. Thanks for the questions. So, as Todd mentioned, we have had 35 meetings with the various mixture of national and regional managed care accounts, and they've gone quite well. There have been scientific presentations to help the managed care organizations understand the benefits of RAYOS. As far as expectations, we expect to primarily focus initially on commercial [lives] [ph] where we would expect to be placed into Tier 3, which puts the patient in the general area of having about a $40 to $50 co-pay. As we have done with DUEXIS, we plan to bring that co-pay down to about an average of $25 for the patient. So, the typical out-of-pocket we would expect for a patient is about $25. So, again, we expect to be in a Tier 3 position in the majority of the accounts, as well as having that plan in place to ensure patients are getting RAYOS at a reasonable out-of-pocket costs similar to what we have done with DUEXIS.
Lisa Bayko - JMP Securities
Okay. In terms of you have had these meetings, when will they convert do you think to actually getting on formulary on that, you know, (inaudible)?
Timothy Walbert
It's less about getting on formulary and more about ensuring access. We expect, at the time of launch, to have a significant amount of RAYOS in the Tier 3 position. Typically in most accounts, you will initially be put into Tier 3 and then go through clinical reviews and P&T reviews over the first six months into the launch. So, we expect initially to have very good access in Tier 3. We don't have a percentage yet, because we haven't introduced the product and gotten some of that direct feedback, we expect to have very good initial access in Tier 3, and over the next several months, we will get a better understanding of what that actual co-pay looks like to a patient and how the overall managed care landscape looks like. But we feel very good about where we are at this point in time.
Lisa Bayko - JMP Securities
Thanks Tim.
(Operator Instructions) Our next question comes from Annabel Samimy of Stifel Nicolaus. Your line is open.
Daniel Chang - Stifel Nicolaus
Hi, this is Daniel Chang in for Annabel. Thanks very much for taking the call. I had a few questions here. I guess firstly just going – I guess diving into the generic switching, have you guys been able to quantify the potential impact of sort of this new strategy of selling to the entire office staff and when might we be able to see some of the updates and results from that?
Timothy Walbert
Thanks Daniel, for the questions. It's Tim. I think we have already started to see the benefit of that. We saw a very strong growth in the month of September versus August. We had new prescriptions of 18% and total prescriptions of 16% and that was still with our existing 80% sales force. And that sales force was, about half of it was new representatives that we brought in over the summer, which has more business-to-business experience and are really focused on driving that full office call to educate, not only physicians that write but office staff to ensure that the patients get the product their physician intended. So, we did see strong acceleration in late August and into September, which is really what we view as results of that renewed focus on really ensuring that the prescription gets pulled through all the way from the physician to the patient picking it up at the pharmacy level.
The acceleration in October, we have seen more results of increasing that critical mass, through that critical mass five-fold increase in called-on physician targets, but we are already starting to see that benefit. We have also the added benefit, with the Mallinckrodt sales force that is calling on 25,000 exclusive targets that also has that same focus of understanding that you need to protect the prescription, ensure that the office staff doesn't allow this pharmacy switching. So, we have already seen initial benefits and we expect that to continue.
Daniel Chang - Stifel Nicolaus
Great. And then, as far as the pilot program is concerned, it sounds like a third-party mailer to pharmacy. At what point do you sort of evaluate whether you want to take this to the next level and blow it up to a full scale national strategy?
Timothy Walbert
So, relative to that program, we have piloted in five states with encouraging results. We are going to evaluate it over the next several weeks, but our plan would be to roll that out fully by the beginning of the year.
Daniel Chang - Stifel Nicolaus
Okay, great. And going on RAYOS, I think you talked yesterday about the promotion for the primary care versus the rheumatologists. Can you just talk about – do you anticipate having the same promotional strategy within the two physician segments and can you talk about what your expected uptake will be once you have the full launch in late January?
Timothy Walbert
Our approach among rheumatologists will be to promote RAYOS in a primary physician and DUEXIS in a secondary physician. When it comes to our over 20,000 primary care targets, we will promote DUEXIS in a primary physician and RAYOS in a secondary physician. And as we said, we will be focusing with RAYOS in the short term with about 1,000 key opinion leaders, rheumatologists over the next several months, with the full launch in late January to ensure that we have got the right preparation, feedback to do the broader launch late January.
We are not commenting at this point on guidance relative to forward-looking prescriptions, but we are able to cover over 90% of all rheumatology prescriptions for products such as methotrexate and generic prednisone with our sales force. So, we are very encouraged by the fact that we have got critical mass right from the start with the launch of RAYOS.
Daniel Chang - Stifel Nicolaus
Great. And then, a couple of financial questions. As far as the deferred revenues are concerned, I think you had about $8.8 million in the quarter. Can you talk about what your expectations are for recognizing those revenues? And then secondly, can you just give us an update on the debt situation after the recent capital raise?
Timothy Walbert
I will take the debt question, Bob, you can take the first one. So, we have a little over $60 million in debt, I think about $61 million with accrued interest and Bob, you can take the first question.
Robert De Vaere
Yes. So, at the end of the third quarter, we had in DUEXIS deferred revenue of about $1.4 million. We are still only about nine or 10 months into the launch of DUEXIS, and there is no bright line for when we would be able to flip that over and recognize revenue on sell-in rather than sell-through. We are certainly working, gathering data and working and refining our estimates of returns and things like that, which there haven't been much of to be honest. So, there is no bright line on when we can flip that over, but we are certainly working to provide support and to make an argument that we should be able to do that sooner rather than later, but at this time, we don't have an estimate of when that will happen.
Daniel Chang - Stifel Nicolaus
Okay, thanks very much.
Thank you. I am showing no further questions in the queue at this time. I will hand the call back to Tim for closing remarks.
Timothy Walbert
Thank you very much for joining us on the call today. Feel free to reach out to the company if you have further questions, and have a great day. Thanks so much.
Thank you. Ladies and gentlemen, this concludes the conference for today. You may all disconnect and have a wonderful day.
Copyright policy: All transcripts on this site are the copyright of Seeking Alpha. However, we view them as an important resource for bloggers and journalists, and are excited to contribute to the democratization of financial information on the Internet. (Until now investors have had to pay thousands of dollars in subscription fees for transcripts.) So our reproduction policy is as follows: You may quote up to 400 words of any transcript on the condition that you attribute the transcript to Seeking Alpha and either link to the original transcript or to www.SeekingAlpha.com. All other use is prohibited.
If you have any additional questions about our online transcripts, please contact us at: email@example.com. Thank you!


text:
WINNER of the November 16 Biweekly Giveaway!
By Giveaways
Thanks to everyone who entered the November 16 iPhone Life Biweekly Giveaway! Every other week we give away amazing prizes, so if you didn't win this time, make sure you enter the November 30 giveaway and tell your friends to enter too!


text:
Philadelphia, PA
Orchestra 2001, conducted by Jayce Ogren, performs Derek Bermel's Tied Shifts
Orchestra 2001, conducted by Jayce Ogren, performs Derek Bermel's Tied Shifts
Derek Bermel and Paquito D'Rivera premiere a new Bermel clarinet duet on a concert featuring D'Rivera's compositions at Music from Copland House.
The New York Festival of Song features songs by Gabriela Lena Frank, Avner Dorman, and Derek Bermel at National Sawdust in Williamsburg.
The Albany Symphony Orchestra, conducted by David Alan Miller, performs Derek Bermel's A shout, a whisper, and a trace at Troy Savings Bank Hall.
Electric Guitar virtuoso and composer D.J. Sparr performs Derek Bermel's Ritornello with the UT New Music Ensemble (Dan Welcher, director).
In collaboration with The Phillips Collection, the University of Maryland School of Music Symphony Orchestra and Jazz Band, conducted by Michael Votta perform Derek Bermel's Migration Series, based on the iconic paintings by Jacob Lawrence.
Derek Bermel is composer-in-residence at Nuova Consonanza «De Musica», featured in concert with Quartetto Indaco at the Accademia Filarmonica Romana, MACRO museum.
The JACK Quartet performs Derek Bermel's Intonations at the Treetops Chamber Music Society.
The Northwestern University Contemporary Music Ensemble, conducted by Alan Pierson, performs Derek Bermel's Canzonas Americanas.
Derek Bermel leads a three-week Master Artist Residency at the Atlantic Center for the Arts (deadline for applications: Sept. 18, 2016).
The JACK Quartet performs the German premiere of Derek Bermel's Intonations at the Elbphilharmonie Kleiner Saal.
Ensemble for These Times performs Derek Bermel's piano trio Death With Interruptions as part of the Guernica Project.
Howard Community College faculty perform Derek Bermel's Twin Trio at the Horowitz Visual and Performing Arts Center.
Derek Bermel serves on the jury of the TCO International Composition Competition and lectures in composition and clarinet at Taipei National University of the Arts.
Emanuele Arciuli performs the Irish premiere of Derek Bermel's Five Funk Studies at the Belfast International Arts Festival.
Emanuele Arciuli performs the Italian premiere of Derek Bermel's Five Funk Studies at the Venice Biennale.
Trombonist David Jackson and the Detroit Chamber Winds and Strings perform Derek Bermel's God's Trombones.
The Sarasota Symphony presents Derek Bermel's Death With Interruptions on their Music of Our Time series.
Derek Bermel is composer-in-residence at the 2016 Classix-Kempten Festival.
Dinosaur Annex performs Derek Bermel's Thracian Sketches at Davis Square Theater.
Derek Bermel is in residence as clarinetist and composer at the Moab Music Festival.
The Locrian Chamber Players perform Derek Bermel's clarinet quintet A Short History of the Universe (as related by Nima Arkani-Hamed) at Riverside Church.
CMI artist faculty perform Derek Bermel's Soul Garden at the Danbury Music Center.
Violist Paul Neubauer performs Derek Bermel's Soul Garden with cellist Tanya Tomkins and the Jupiter Quartet at the Music in the Vineyards Festival.
Electric guitarist Derek Johnson performs Ritornello with members of the Bowdoin Festival faculty.
The Madeline Island Chamber Music Festival presents the Prairie Winds Quintet performing Derek Bermel's Wanderings.
Jun Iwasaki, Brant Taylor, and John Novacek perform Derek Bermel's piano trio Death with Interruptions at the Mimir Festival.
Violist Ara Gregorian performs Derek Bermel's Soul Garden with the Bach Dancing and Dynamite Society.
The Seattle Symphony, conducted by Ludovic Morlot, performs Derek Bermel's Elixir.
Violist Nadia Sirota performs Derek Bermel's Soul Garden at the Next Festival for Emerging Artists Festival. Conducted by Peter Aksim.
The JACK Quartet premieres a new work by Derek Bermel as part of the New York Philharmonic Biennial at the 92nd Street Y.
A Far Cry performs the East Coast premiere of Derek Bermel's Murmurations for string orchestra.
The Stony Brook Chamber Ensemble presents the Parhelion Trio, performing Derek Bermel's Twin Trio.
Derek Bermel's Death With Interruptions receives its European Premiere at Ferrara Music in Italy. Emanuele Arciuli, piano; Gabriele Pieranunzi, violin; Shana Downes, cello
The Albany Symphony performs Derek Bermel's Mar de Setembro featuring soprano Sara Serpa, and conducted by David Alan Miller.
April 16th 7:30pm
April 17th 3:00pm
Asko Schonberg Ensemble performs Derek Bermel's Canzonas Americanas.
March 17th 8:15pm Amsterdam, Muziekgebouw aan 't IJ
March 18th 8:00pm Utrecht, Tivolivredenburg
March 24th 8:15pm Nijmegen, Concertgebouw De Vereeniging
Derek Bermel's "Coming Together" will be performed by members of the National Arts Centre Orchestra.
Death with Interruptions
Emanuele Arciuli, piano; Gabriele Pierannunzi, violin; Shana Downes, cello
Firenze, Italy
6:30 pm pre-concert discussion with CCMF Composer-in-Residence Derek Bermel
The Calyx Piano Trio returns to New Bern to conclude season thirteen with a program of heart-rending music reflecting on loss and joy. Works include Dvorak's Piano Trio in f minor, Op. 65;Deep River (a spiritual popularized by Dvorak's American associate Henry Thacker Burleigh); and the North Carolina premiere of Death with Interruptions by celebrated American composer Derek Bermel. Reception to follow.
Tickets $30
St. Paul Chamber Orchestra plays Derek Bermel's Murmurations.
Jan 22nd 10:30am Ordway Concert Hall
Jan 22nd 8:00pm Ordway Concert Hall
Jan 23rd 8:00pm Ordway Concert Hall
JAn 24th 2:00pm Benson Great Hall


text:
Flame of Recca, Vol. 18
Setup Price Alert
GBP£5.99New Kobo UK
In stock
Recca and crew are deep in a spooky cave seeking out a dangerous weapon known as Tendo Jigoku, which in the wrong hands will spell disaster for the world. But it's a race against time as their nemesis-the bloodthirsty madman Mori-is seeking it as well. After getting lost in the cave, the group decides to split up. Things take a turn for the worse when Domon and Fuko find themselves in a fight to the death with two warriors who easily defeated them both once before. Can they muster up enough tough stuff to out-rough these ruffians?
|Product Details
|VIZ Media: Action
|VIZ Media: Action


text:
Project Main Details
***** is a premiere digital publisher focused on creating award-winning interactive children's stories for the iPad and other tablet devices. We collaborate with authors, illustrators and publishers to turn their stories into educational, engaging and entertaining experiences. *****'s patented technology (************) brings any illustration style to life through animation and interactivity. Kirkus Reviews, Fast Company, NPR, PadGadget and Animation Magazine all herald Auryn as a leader in creating sophisticated and immersive "app" experiences.
PROJECT: ****************** - iPad Books for Children
Prefer a young male or male child's voice.
Talent must record and deliver professional quality audio files.
Talent will do readings of each of the stories, 8 total, and then must read a list of individual words for the apps pronunciation feature.
Talent must use Skype or conference call during sessions with director/producer of project. There will be 3 or 4 sessions each about an hour to 90 minutes long. 2012-01-03 19:24:52 GMT 2012-01-07 16:00:00 (GMT -08:00) Pacific Time (US & Canada) Yes (click here to learn more about ) Closed 0 0 0 direct invitation(s) have been sent by the voice seeker resulting in 0 audition(s) and/or proposal(s) so far. Voice123 SmartCast is seeking 50 auditions and/or proposals for this project (approx.) Invitations sent by SmartCast have resulted in 0 audition(s) and/or proposal(s) so far.
Project Parameters
• Audio files must be delivered via FTP/Dropbox/Google Drive/cloud
Script Details
Katie sat under a tree
reading a book
and eating a peach,
and when she got down
to the last sweet bite,
she threw away the pit-
not straight ahead,
not to her right,
nor to her left
where the story
might have stopped,
but over her shoulder,
not watching where it went,
and that's how it became
the perilous pit
Voice-Seeker Details
Voice123 Team Comments
Voice123 consultations with this voice seeker regarding this project and/or other projects by this voice seeker, via phone, chat, and/or email.
This project - phone.
Previous projects - phone.
This project - email or chat.
Previous projects - email or chat.
Corporate web site for this voice-seeker confirmed by Voice123
Note: Voice123 strives to establish the legitimacy of all projects posted. However, Voice123 subscribers and users are responsible for confirming information stated by prospective voice seekers, agents and/or clients. Voice123 subscribers and users assume all liability for use of any information found through Voice123, or any of its publications.
This page contains the most important details of this project. If you find the information on this project inaccurate or inappropriate, please let us know by contacting us.


text:
Win up to $30,000!
The more you use your debit card, the more chances you have to win.
Here. There. Everywhere.
We'll keep you connected with mobile access and on-the-go banking tools.
Drive it. Love it. Buy it.
We'll help you get it with low-rate financing and an Ent Extras ® rebate.
Community Spotlight
The March of Dimes helps moms have full-term pregnancies and healthy babies. And if something goes wrong, they offer information and comfort to families. Since its founding in 1938, March of Dimes has consistently excelled at bringing together key stakeholders to address some of the world's gravest child health challenges.